Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-14T13:51:18.553Z Has data issue: false hasContentIssue false
  • English
  • Français

Congenital heart block: current thoughts on management, morphologic spectrum, and role of intervention

Published online by Cambridge University Press:  23 September 2014

Teresa Alvarez Martin
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Original Article
Information
Cardiology in the Young , Volume 24 , Issue S2: Fetal cardiovascular medicine: current perspectives and future hopes , October 2014 , pp. 41 - 46
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.O’Connor, MJ, Shah, MJ. Arrhythmias in the fetus. In: Rychik J, Tian Z (eds). Foetal Cardiovascular Imaging. Elsevier Saunders, Philadelphia, PA, 2012: 477–491.Google Scholar
2.Schmidt, KG, Ulmer, HE, Silverman, NH, et al. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol 1991; 17: 1360–1366.CrossRefGoogle ScholarPubMed
3.Friedman, DM, Rupel, A, Buyon, JP. Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007; 9: 101–108.CrossRefGoogle ScholarPubMed
4.Buyon, JP, Hiebert, R, Copel, J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a National Neonatal Lupus Registry. J Am Coll Cardiol 1998; 31: 1658–1666.CrossRefGoogle ScholarPubMed
5.Buyon, JP, Clancy, RM, Friedman, DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med 2009; 265: 653–662.CrossRefGoogle ScholarPubMed
6.De Carolis, S, Salvi, S, Botta, A, et al. Which intrauterine treatment for autoimmune congenital heart block? Open Autoimmun J 2010; 2: 1–10.Google Scholar
7.Buyon, JP, Waltuck, J, Caldwell, K, et al. Relationship between maternal and neonatal levels of antibodies to 48kDa SSB(La), 52kDa SSA(Ro), and 60kDa SSA(Ro) in pregnancies complicated by congenital heart block. J Rheumatol 1994; 21: 1943–1950.Google Scholar
8.Qu, Y, Boutjdir, M. Pathophysiology of autoimmune-associated congenital heart block. Appl Cardiopulm Pathophysiol 2012; 16: 96–112.Google Scholar
9.Buyon, JP, Clancy, RM. Autoimmune-associated congenital heart block: dissecting the cascade from immunologic insult to relentless fibrosis. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: 1027–1035.Google Scholar
10.Wahren-Herlenius, M, Sonesson, SE. Specificity and effector mechanisms of autoantibodies in congenital heart block. Curr Opin Immunol 2006; 18: 690–696.CrossRefGoogle ScholarPubMed
11.Buyon, JP, Clancy, RM. Dying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block. Lupus 2008; 17: 86–90.CrossRefGoogle ScholarPubMed
12.Clancy, RM, Kapur, RP, Molad, Y, et al. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004; 50: 173–182.CrossRefGoogle ScholarPubMed
13.Clancy, RM, Neufing, PJ, Zheng, P, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116: 2413–2422.Google ScholarPubMed
14.Karnabi, E, Boutjdir, M. Role of calcium channels in congenital heart block. Scand J Immunol 2010; 72: 226–234.CrossRefGoogle ScholarPubMed
15.Mangoni, ME, Couette, B, Bourinet, E, et al. Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity. Proc Natl Acad Sci USA 2003; 100: 5543–5548.CrossRefGoogle ScholarPubMed
16.Friedman, DM, Kim, MY, Copel, JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485–493.CrossRefGoogle ScholarPubMed
17.Sonesson, SE, Salomonsson, S, Jacobsson, LA, et al. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253–1261.CrossRefGoogle ScholarPubMed
18.Rein, AJ, Mevorach, D, Perles, Z, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009; 119: 1867–1872.CrossRefGoogle ScholarPubMed
19.Gardiner, HM, Belmar, C, Pasquini, L, et al. Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies. Heart 2007; 93: 1454–1460.CrossRefGoogle ScholarPubMed
20.Mevorach, D, Elchalal, U, Rein, AJ. Prevention of complete heart block in children of mothers with anti-SSA/Ro and antiSSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. Curr Opin Rheumatol 2009; 21: 478–482.CrossRefGoogle Scholar
21.Jaeggi, ET, Silverman, ED, Laskin, C, et al. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol 2011; 57: 1487–1492.CrossRefGoogle Scholar
22.Friedman, DM, Kim, MY, Copel, JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) study. Am J Cardiol 2009; 103: 1102–1106.CrossRefGoogle ScholarPubMed
23.Moak, JP, Barron, KS, Hougen, TJ, et al. Congenital heart block: development of late onset cardiomyopathy, a previously underappreciated sequela. J Am Col Cardiol 2001; 37: 238–242.CrossRefGoogle ScholarPubMed
24Nield, LE, Silverman, ED, Smallhorn, JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40: 796–802.CrossRefGoogle ScholarPubMed
25.Nield, LE, Silverman, ED, Taylor, GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105: 843–848.CrossRefGoogle ScholarPubMed
26.Trucco, SM, Jaeggi, E, Cuneo, B, et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol 2011; 57: 715–723.CrossRefGoogle ScholarPubMed
27.Friedman, DM, Llanos, C, Izmirly, PM. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block. Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62: 1138–1146.CrossRefGoogle Scholar
28.Pisoni, CN, Brucato, A, Ruffatti, A, Espinosa, G. Failure of intravenous immunoglobulin to prevent congenital heart block. Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62: 1147–1152.CrossRefGoogle ScholarPubMed